Artiva Biotherapeutics (ARTV) Institutional Ownership $6.53 -0.25 (-3.69%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Institutional Ownership Changes (13F Filings) for Artiva Biotherapeutics (NASDAQ:ARTV)Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$178.44MNumber ofInstitutional Sellers(last 12 months)0 Get ARTV Insider Trade Alerts Want to know when executives and insiders are buying or selling Artiva Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ARTV Institutional Buying and Selling by Quarter Artiva Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails12/26/2024JPMorgan Chase & Co.10,726$166K0.0%N/A0.044% 11/27/2024Franklin Resources Inc.520,301$7.44M0.0%N/A2.142% 11/19/2024Barclays PLC19,616$304K0.0%N/A0.081% 11/16/2024Geode Capital Management LLC308,930$4.77M0.0%N/A1.272% 11/15/2024Barclays PLC19,616$304K0.0%N/A0.081% 11/15/2024Wellington Management Group LLP194,108$2.91M0.0%N/A0.799% 11/15/2024State Street Corp86,559$1.34M0.0%N/A0.356% 11/15/2024Samsara BioCapital LLC291,666$4.51M0.9%N/A1.201% 11/15/2024RA Capital Management L.P.9,853,302$152.23M1.8%N/A40.565% 11/15/2024RTW Investments LP148,844$2.30M0.0%N/A0.613% 11/14/2024Acuta Capital Partners LLC44,000$680K0.6%N/A0.181% 11/14/2024MetLife Investment Management LLC8,733$135K0.0%N/A0.036% 11/13/2024BNP Paribas Financial Markets2,728$42K0.0%N/A0.011% 11/12/2024Charles Schwab Investment Management Inc.40,293$623K0.0%N/A0.166% (Data available from 1/1/2016 forward) ARTV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ARTV shares? During the previous two years, 13 institutional investors and hedge funds held shares of Artiva Biotherapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($152.23M), Franklin Resources Inc. ($7.44M), Geode Capital Management LLC ($4.77M), Samsara BioCapital LLC ($4.51M), Wellington Management Group LLP ($2.91M), RTW Investments LP ($2.30M), and State Street Corp ($1.34M).Learn more on ARTV's institutional investors. Which institutional investors have been buying Artiva Biotherapeutics stock? Of the 13 institutional investors that purchased Artiva Biotherapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($9.85M), Franklin Resources Inc. ($520.30K), Geode Capital Management LLC ($308.93K), Samsara BioCapital LLC ($291.67K), Wellington Management Group LLP ($194.11K), RTW Investments LP ($148.84K), and State Street Corp ($86.56K). How much institutional buying is happening at Artiva Biotherapeutics? Institutional investors have bought a total of 11,549,422 shares in the last 24 months. This purchase volume represents approximately $178.44M in transactions. Related Companies CDMO Major Shareholders SANA Major Shareholders TYRA Major Shareholders AVDL Major Shareholders SEPN Major Shareholders CRON Major Shareholders IMTX Major Shareholders REPL Major Shareholders BCAX Major Shareholders PLRX Major Shareholders This page (NASDAQ:ARTV) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
